Prostate Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035
Prostate
Cancer Market Outlook
Thelansis’s “Prostate Cancer
Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report
– 2025 To 2035” covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Prostate
Cancer treatment modalities options for eight major markets (USA,
Germany, France, Italy, Spain, UK, Japan, and China).
Prostate
Cancer Overview
Prostate cancer is the most common
malignancy in men, arising from prostatic glandular epithelium driven by
androgen receptor signalling, with somatic alterations in PTEN, TP53, RB1, and
DNA repair genes including BRCA1, BRCA2, and CDK12 underpinning aggressive and
castration-resistant disease biology. Patients present with urinary symptoms,
elevated PSA, or incidentally detected nodules, with many diagnosed through
PSA-based screening programmes; multiparametric MRI and targeted biopsy have
refined diagnostic precision, while PSMA PET-CT represents the current standard
for sensitive metastatic staging. Gleason grading and clinical staging guide
risk stratification and therapeutic intensity. Localised disease is managed
with active surveillance in low-risk disease, radical prostatectomy, or
radiotherapy with or without androgen deprivation therapy. Metastatic
hormone-sensitive disease is addressed with androgen deprivation therapy
combined with novel androgen receptor pathway inhibitors including enzalutamide,
apalutamide, or darolutamide, or docetaxel in high-volume disease.
Castration-resistant prostate cancer is managed with enzalutamide, abiraterone,
cabazitaxel, or radium-223 for bone-predominant disease. PARP inhibitors
olaparib and rucaparib address homologous recombination repair-deficient
disease, while pembrolizumab targets MSI-H or TMB-high tumours. Lutetium-177
PSMA-617 represents a transformative radioligand therapy for PSMA-positive
metastatic castration-resistant disease. Prognosis varies considerably with
stage and molecular features; multidisciplinary management, bone health
optimisation, and patient-centred quality-of-life considerations are integral
to long-term care.
Geography
coverage:
G8 (United
States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights
driven by robust research, including:
- In-depth interviews with leading KOLs
and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based
automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2025–2035)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool (e.g.,
drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the most
promise, and what is their potential for launch and future positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment